United Therapeutics (UTHR) EV to EBIT (2009 - 2026)

United Therapeutics has disclosed EV to EBIT across 18 years of filings, most recently posting 61.85 for Q2 2026.

• In Q2 2026, EV to EBIT rose 126.73% year-over-year to 61.85; the TTM figure through Jun 2026 stood at 14.6 (up 112.56% YoY), while the FY2025 annual figure was 12.29, up 34.85% from the prior year.
• EV to EBIT came in at 61.85 for Q2 2026 at United Therapeutics, down from 70.12 in the prior quarter.
• In the past five years, EV to EBIT ranged from a high of 70.12 in Q1 2026 to a low of 20.34 in Q1 2022.
• Average EV to EBIT over 5 years is 36.08, with a median of 31.6 recorded in 2024.
• Year-over-year, EV to EBIT slumped 50.19% in 2023 and jumped 153.84% in 2026.
• Over 5 years, EV to EBIT stood at 56.73 in 2022, then tumbled by 50.19% to 28.26 in 2023, then rose by 24.18% to 35.09 in 2024, then surged by 46.57% to 51.43 in 2025, then gained by 20.27% to 61.85 in 2026.
• Per Business Quant data, the three most recent EV to EBIT figures were 61.85 in Q2 2026, 70.12 in Q1 2026, and 51.43 in Q4 2025.